BSP:BIIB34 (USA)  
Biogen Inc logo

Biogen Inc

R$ 187.63 (0%) Aug 16
On watch
P/E:
15.67
P/B:
2.69
Market Cap:
R$ 164.02B ($ 31.86B)
Enterprise V:
R$ 176.54B ($ 34.30B)
Volume:
-
Avg Vol (2M):
334.00
Also Trade In:
Volume:
-
Market Cap R$:
164.02B
Market Cap $:
31.86B
PE Ratio:
15.67
Avg Vol (2-Month):
334.00
Enterprise Value R$:
176.54B
Enterprise Value $:
34.30B
PB Ratio:
2.69
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Biogen Inc
NAICS : 325412 SIC : 2834
225 Binney Street, Cambridge, MA, USA, 02142
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Financials (Next Earnings Date:2022-10-20 Est.)

BSP:BIIB34's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil R$) 55,797.428
EPS (TTM) (R$) 12.061
Beta -0.16
Volatility % 27.09
14-Day RSI 51.66
14-Day ATR (R$) 2.31046
20-Day SMA (R$) 188.211
12-1 Month Momentum % -34.5
52-Week Range (R$) 157.76 - 313.69
Shares Outstanding (Mil) 874.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biogen Inc Filings

Document Form Filing Date
No Filing Data